After canceling a routine meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review the composition of the 2025-2026 influenza vaccine, the US Food and Drug Administration (FDA) on Thursday announced its recommendations for strain selection following a closed-door meeting with other government agencies.
The meeting was not previously announced or open to the public and took place the same day as the previously scheduled VRBPAC meeting would have taken place, though the agency released slides and an agenda for the meeting after it took place. The hour-and-a-half-long meeting was attended by officials from FDA, the Centers for Disease Control and Prevention, and the Department of Defense, and was called to a close 55 minutes before it was scheduled to end, according to a summary released by FDA…
